Cassava sciences reports q3 2024 financial and operating results

Austin, texas, nov. 07, 2024 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on developing a novel treatment for alzheimer's disease, today reported financial results for the third quarter ended september 30, 2024.

SAVA Ratings Summary

SAVA Quant Ranking